TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

被引：0

作者：

Forster, M. ^{[1
]}

Krebs, M. ^{[2
,3
]}

Majem, M. ^{[4
]}

Peguero, J.

Clay, T. ^{[5
]}

Felip, E. ^{[6
]}

Iams, W. ^{[7
]}

Roxburgh, P. ^{[8
,9
]}

Doger, B. ^{[10
]}

Bajaj, P. ^{[11
]}

Kefas, J. ^{[12
]}

Scott, J. A. ^{[13
]}

Joaquin, A. Barba ^{[4
]}

Mueller, C. ^{[14
]}

Triebel, F. ^{[15
]}

机构：

[1] Univ Coll London Hosp NHS Fdn, Canc Inst, UCL, London, England

[2] Univ Manchester, Div Canc Sci, Manchester, England

[3] Christie NHS Fdn Trust, Manchester, England

[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[5] Hosp St John God Subiaco, Perth, Australia

[6] Vall Hebron Univ Hosp, Barcelona, Spain

[7] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN USA

[8] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Scotland

[9] Beatson West Scotland Canc Ctr, Glasgow, Scotland

[10] Fdn Jimenez Diaz, Madrid, Spain

[11] Tasman Oncol, Southport, Australia

[12] Univ Coll London Hosp NHS Trust, London, England

[13] Christie NHS Fdn Trust, Manchester, England

[14] Immutep GmbH, Berlin, Germany

[15] Immutep SAS, Orsay, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

LAG-3; NSCLC; PD-1/PD-L1; refractory;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.01-10

引用

页码：S395 / S395

页数：1

共 50 条

[21] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
VanderWalde, Ari
Bellasea, Shay L.
Kendra, Kari L.
Khushalani, Nikhil I.
Campbell, Katie M.
Scumpia, Philip O.
Kuklinski, Lawrence F.
Collichio, Frances
Sosman, Jeffrey A.
Ikeguchi, Alexandra
Victor, Adrienne I.
Truong, Thach-Giao
Chmielowski, Bartosz
Portnoy, David C.
Chen, Yuanbin
Margolin, Kim
Bane, Charles
Dasanu, Constantin A.
Johnson, Douglas B.
Eroglu, Zeynep
Chandra, Sunandana
Medina, Egmidio
Gonzalez, Cynthia R.
Baselga-Carretero, Ignacio
Vega-Crespo, Agustin
Garcilazo, Ivan Perez
Sharon, Elad
Hu-Lieskovan, Siwen
Patel, Sapna P.
Grossmann, Kenneth F.
Moon, James
Wu, Michael C.
Ribas, Antoni
NATURE MEDICINE, 2023, 29 (09) : 2278 - +
[22] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Ari VanderWalde
Shay L. Bellasea
Kari L. Kendra
Nikhil I. Khushalani
Katie M. Campbell
Philip O. Scumpia
Lawrence F. Kuklinski
Frances Collichio
Jeffrey A. Sosman
Alexandra Ikeguchi
Adrienne I. Victor
Thach-Giao Truong
Bartosz Chmielowski
David C. Portnoy
Yuanbin Chen
Kim Margolin
Charles Bane
Constantin A. Dasanu
Douglas B. Johnson
Zeynep Eroglu
Sunandana Chandra
Egmidio Medina
Cynthia R. Gonzalez
Ignacio Baselga-Carretero
Agustin Vega-Crespo
Ivan Perez Garcilazo
Elad Sharon
Siwen Hu-Lieskovan
Sapna P. Patel
Kenneth F. Grossmann
James Moon
Michael C. Wu
Antoni Ribas
Nature Medicine, 2023, 29 : 2278 - 2285
[23] TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
Adkins, Douglas
Cheshuk, Valerii
Peguero, Julio Antonio
Park, John J.
Lopez-Pousa, Antonio
Lybaert, Willem
Brana, Irene
Doger, Bernard
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
Jeong, Seri
Lee, Nuri
Park, Min-Jeong
Jeon, Kibum
Song, Wonkeun
CANCERS, 2021, 13 (20)
[25] PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
Wang, Jaeyun Jane
Burger, Peter
Taube, Janis
Soni, Abha
Chaichana, Kaisorn
Sheu, Mary
Belcaid, Zineb
Jackson, Christopher
Lim, Michael
CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (12)
[26] Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
Marcq, Elly
De Waele, Jorrit
Van Audenaerde, Jonas
Lion, Eva
Santermans, Eva
Hens, Niel
Pauwels, Patrick
van Meerbeeck, Jan P.
Smits, Evelien L. J.
ONCOTARGET, 2017, 8 (52) : 89722 - 89735
[27] Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
Krebs, Matthew G.
Forster, Martin
Majem, Margarita
Peguero, Julio
Iams, Wade
Clay, Tim
Roxburgh, Patricia
Doger, Bernard
Bajaj, Pawan
Barba, Andres
Perera, Suvini
Mueller, Christian
Triebel, Frederic
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (11):
[28] Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up
Marmarelis, M. E.
Cantor, D. J.
Mathew, D.
McWilliams, T.
Bauml, J.
Hwang, W-T
Singh, A.
D'Avella, C.
Davis, C.
Ye, D.
Sun, L.
Ciunci, C.
Aggarwal, C.
Cohen, R. B.
Minn, A.
Wherry, J.
Langer, C. J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S20 - S20
[29] A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
Al-Batran, S. -E.
Mueller, D. W.
Rafiyan, M. -R
Kiselicki, D.
Atmaca, A.
Habibzada, T.
Mueller, C.
Brignone, C.
Triebel, F.
Loose, M.
Schaaf, M.
Sookthai, D.
Eickhoff, R.
Jaeger, E.
Goetze, T. O.
ESMO OPEN, 2023, 8 (05)
[30] Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study
Metcalf, R.
Laban, S.
Kristensen, C. A.
Ciuleanu, T-E.
Brana, I.
Rivas, A. Soria
Dieter, S. M.
Bols, A.
Forster, M. D.
Covela, M. R.
Christian, J.
Vogl, F. D.
Mueller, C.
Triebel, F.
ANNALS OF ONCOLOGY, 2024, 35 (08) : 754 - 755

← 1 2 3 4 5 →